Janessa Laskin

9.9k total citations · 1 hit paper
187 papers, 3.8k citations indexed

About

Janessa Laskin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Janessa Laskin has authored 187 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Oncology, 109 papers in Pulmonary and Respiratory Medicine and 62 papers in Cancer Research. Recurrent topics in Janessa Laskin's work include Lung Cancer Treatments and Mutations (90 papers), Cancer Genomics and Diagnostics (60 papers) and Lung Cancer Research Studies (30 papers). Janessa Laskin is often cited by papers focused on Lung Cancer Treatments and Mutations (90 papers), Cancer Genomics and Diagnostics (60 papers) and Lung Cancer Research Studies (30 papers). Janessa Laskin collaborates with scholars based in Canada, United States and Germany. Janessa Laskin's co-authors include Alan B. Sandler, Cheryl Ho, Diana N. Ionescu, Nevin Murray, Samuel Leung, Daniel J. Renouf, Marco A. Marra, Allen M. Gown, Tony Mok and Yi‐Long Wu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Janessa Laskin

172 papers receiving 3.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

2017 398 citations Janessa Laskin, Scott A. Laurie et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Janessa Laskin Canada	30	2.2k	2.1k	1.0k	774	299	187	3.8k
Yasushi Goto Japan	30	2.5k 1.1×	2.2k 1.1×	854 0.8×	602 0.8×	213 0.7×	246	3.8k
Tommaso De Pas Italy	33	2.5k 1.1×	2.1k 1.0×	975 0.9×	620 0.8×	417 1.4×	151	4.3k
Mauro Papotti Italy	37	1.7k 0.8×	2.7k 1.3×	1.3k 1.3×	1.1k 1.4×	475 1.6×	96	4.6k
Yoshitsugu Horio Japan	32	2.3k 1.1×	2.6k 1.3×	1.3k 1.3×	660 0.9×	276 0.9×	102	4.1k
Charu Aggarwal United States	35	2.6k 1.2×	1.9k 0.9×	889 0.8×	801 1.0×	341 1.1×	202	4.1k
Peter Langmuir United States	30	1.8k 0.8×	1.6k 0.8×	1.3k 1.3×	507 0.7×	320 1.1×	56	4.7k
Kiyotaka Yoh Japan	35	3.0k 1.4×	2.6k 1.3×	1.4k 1.3×	740 1.0×	350 1.2×	271	4.6k
Luis E. Raez United States	37	2.2k 1.0×	1.7k 0.8×	1.8k 1.7×	1.2k 1.5×	573 1.9×	224	4.6k
Rosalyn A. Juergens Canada	30	3.1k 1.4×	1.9k 0.9×	1.2k 1.1×	599 0.8×	196 0.7×	125	4.3k
Hyo Sup Shim South Korea	37	2.4k 1.1×	3.1k 1.5×	1.5k 1.4×	1.1k 1.4×	429 1.4×	164	5.1k

Countries citing papers authored by Janessa Laskin

Since Specialization

Citations

This map shows the geographic impact of Janessa Laskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janessa Laskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janessa Laskin more than expected).

Fields of papers citing papers by Janessa Laskin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janessa Laskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janessa Laskin. The network helps show where Janessa Laskin may publish in the future.

Co-authorship network of co-authors of Janessa Laskin

This figure shows the co-authorship network connecting the top 25 collaborators of Janessa Laskin. A scholar is included among the top collaborators of Janessa Laskin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janessa Laskin. Janessa Laskin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garassino, Marina Chiara, Yong He, Myung‐Ju Ahn, et al.. (2025). Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 202. 108417–108417.

Culibrk, Luka, Jasleen Grewal, Erin Pleasance, et al.. (2024). Robust Somatic Copy Number Estimation using Coarse-to-fine Segmentation. Current Bioinformatics. 20(9). 789–803.

Wells, J. Connor, et al.. (2024). Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial. Lung Cancer. 190. 107529–107529. 3 indexed citations

Titmuss, Emma, Irene Yu, Erin Pleasance, et al.. (2024). Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Oncology. 31(4). 1865–1875. 1 indexed citations

Csizmók, Veronika, Cameron J. Grisdale, Laura Williamson, et al.. (2024). Diagnostic and Therapeutic Implications of a FUS::TFCP2 Fusion and ALK Activation in a Metastatic Rhabdomyosarcoma. Genes Chromosomes and Cancer. 63(9). e23259–e23259. 3 indexed citations

Romero, Joan Miguel, Emma Titmuss, Yifan Wang, et al.. (2023). Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers. npj Precision Oncology. 7(1). 73–73. 8 indexed citations

Leung, Bonnie, Mitchell Liu, Eric Berthelet, et al.. (2023). Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression. Current Oncology. 30(8). 7499–7507. 7 indexed citations

Li, Kelly, Ian Bosdet, Stephen Yip, et al.. (2023). Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer. Current Oncology. 30(8). 7099–7111. 1 indexed citations

Barnes, T., Janessa Laskin, Parneet Cheema, et al.. (2023). The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report. JTO Clinical and Research Reports. 5(1). 100615–100615. 1 indexed citations

10.

Wang, Yuzhuo, Sujung Yeo, Pat G. Camp, et al.. (2023). 2129P Feasibility of a virtual exercise program to mitigate decline in physical function for advanced lung cancer patients. Annals of Oncology. 34. S1111–S1111.

11.

Garassino, Marina Chiara, Willemijn S.M.E. Theelen, Robert M. Jotte, et al.. (2023). LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Annals of Oncology. 34. S1309–S1310. 37 indexed citations

12.

Yip, Stephen, Barbara Melosky, Cheryl Ho, et al.. (2022). Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current Oncology. 30(1). 145–156. 2 indexed citations

13.

Titmuss, Emma, Alexandra Pender, James T. Topham, et al.. (2022). The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. Journal of Molecular Diagnostics. 24(6). 609–618. 7 indexed citations

14.

Ezeife, Doreen A., Eldon Spackman, Rosalyn A. Juergens, et al.. (2022). The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 14. 27 indexed citations

15.

Laurie, Scott A., Jason Agulnik, Desirée Hao, et al.. (2020). 1195P The value of detecting resistance through liquid biopsy. Annals of Oncology. 31. S786–S787. 1 indexed citations

16.

Mendis, Shehara, Miguel Alcaide, James T. Topham, et al.. (2020). Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. Clinical Colorectal Cancer. 19(2). 132–136.e3. 1 indexed citations

17.

Ronsley, Rebecca, Shahrad R. Rassekh, Yaoqing Shen, et al.. (2018). Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma. Molecular Case Studies. 4(2). a002568–a002568. 12 indexed citations

18.

Grewal, Jasleen, Peter Eirew, Martin Jones, et al.. (2017). Detection and genomic characterization of a mammary-like adenocarcinoma. Molecular Case Studies. 3(6). a002170–a002170. 10 indexed citations

19.

Noonan, Krista, Janessa Laskin, Yulong Zheng, et al.. (2015). Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population. Clinical Oncology. 27(9). 505–513. 4 indexed citations

20.

Hamilton, Sarah, Paul Mak, Gwo Fuang Ho, Janessa Laskin, & Joanne Wu. (2013). Nasopharyngeal Carcinoma (NPC) in British Columbia (BC): A Population-Based Comparison of Asian and Non-Asian Patients. International Journal of Radiation Oncology*Biology*Physics. 87(2). S446–S446. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact